Biomedical subjects

Aldo J Peixoto

Publications and source records attributed to Aldo J Peixoto.

13 recordsLinked to original sources

PubMed2006

Reliability of a noninvasive device to measure systemic hemodynamics in hemodialysis patients.

OBJECTIVE: To evaluate the reliability of a noninvasive hemodynamic monitor in hemodialysis patients. METHODS: We enrolled 15 male patients (mean age 63+/-12 years) on stable chronic hemodialysis. Blood pressure and hemodynamic readings were obtained with the Dynapulse 500 Guardian device (Pulsemetric Inc., San Diego, California, USA), which measures systemic hemodynamics on the basis of oscillometric waveforms obtained through a cuff placed over the brachial artery. Measurements were taken sequentially, in duplicate, before, during and after hemodialysis, in the supine, seated and standing positions on four separate midweek dialysis sessions over a 2-week period. RESULTS: The repeatability of the method was tested using 200 pairs of valid measurements. The average values (+/-SD) were 137+/-22 mmHg for systolic blood pressure, 80+/-13 mmHg for diastolic blood pressure, 76+/-15 bpm for heart rate, 1320+/-268 mmHg/s for dP/dtmax, 2.8+/-0.5 l/min/m for cardiac index, and 1455+/-359 dyn/s/cm for systemic vascular resistance. The mean differences (+/-SD of the difference) between readings were 0.1+/-10.4 mmHg for systolic blood pressure, 0.3+/-6.0 mmHg for diastolic blood pressure, -0.2+/-8.0 bpm for heart rate, 0.2+/-234 mmHg/s for dP/dtmax, 0.03+/-0.26 l/min/m for cardiac index and -10+/-177 for systemic vascular resistance, yielding limits of agreement (95%) of -20 to 20 mmHg for systolic blood pressure, -11 to 12 mmHg for diastolic blood pressure, -16 to 17 bpm for heart rate, -458 to 458 mmHg/s for dP/dtmax, -0.5 to 0.5 l/min/m for cardiac index and -338 to 357 dyn/s/cm for systemic vascular resistance. Other hemodynamic parameters fared similarly, and coefficients of variation were all between 7 and 18%. CONCLUSION: We conclude that the Dynapulse 500 Guardian has adequate reliability indices in hemodialysis patients.

Aged↗

PubMed2006

Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis.

Arterial stiffness is an independent cardiovascular prognostic factor and is modulated by angiotensin-converting enzyme inhibitors (ACEIs). The authors performed a meta-analysis of clinical trials investigating the effects of ACEIs on pulse wave velocity (PWV) or augmentation index. The search included randomized clinical trials as well as uncontrolled studies that measured in-treatment changes in arterial stiffness. The authors performed separate analyses for carotid-femoral PWV, brachioradial PWV, and augmentation index. Average absolute and relative reduction in mean arterial pressure and PWV were -15.4 mm Hg and -13.04% and -1.15 m/s and -9.74% for carotid-femoral PWV studies; and -11.2 mm Hg and -9.3% and -1.9 m/s and -16.7% for brachioradial PWV studies. There was a greater reduction in augmentation index by ACEIs when compared with controls (-1.0% to -5.3%). The authors conclude that ACEIs have modest beneficial effects on arterial stiffness measured as PWV and augmentation index, and this effect is at least partly independent of changes in blood pressure.

Angiotensin-Converting Enzyme Inhibitors↗

PubMed2006

Comparison of side hole versus non side hole high flow hemodialysis catheters.

Current literature suggests that side holes may be detrimental to dialysis catheter performance. Today, these catheters are primarily available with side holes. The purpose of this study was to compare flow rates, infection rate, and survival of side hole vs. non side hole hemodialysis catheters. Over a 16-month period patients were arbitrarily assigned to either a 14.5 F MAHURKAR MAXID cuffed dual lumen tunneled catheter with side holes or a 14.5 F MAHURKAR MAXID cuffed dual lumen tunneled catheter without side holes ("non side hole catheters"). We performed a retrospective analysis of catheter flow rates, patency, catheter survival, and catheter-related infections. Information was gathered for the life of the catheter or up to 28 weeks. A total of 54 patients were enrolled in the study. Thirty-seven of 54 (68%) patients received a catheter with side holes for a total of 3,930 catheter days and 17/54 (32%) received a similar catheter without side holes for a total of 2,188 catheter days. Catheter infection necessitating removal of the catheter occurred in 10/37 catheters with side holes and 1/17 without side holes. Infection rates per 1,000 catheter days were 2.545 with side holes and 0.254 without side holes (p<0.001). Slightly improved catheter survival (p<0.05) was recorded with the non side hole catheters. No insertion complication (e.g., air embolization, bleeding, or kinking) occurred with either catheter. One catheter without side holes had to be repositioned 5 days after insertion because of poor flows. No significant difference was recorded in mean blood flow rates between the catheters. Results indicate reduced catheter infection rate in hemodialysis patients with the use of non side hole dual lumen tunneled cuffed catheters.

Catheters, Indwelling↗

PubMed2005

Arterial compliance in elderly men with chronic kidney disease.

BACKGROUND/AIM: Chronic kidney disease (CKD) is associated with decreased arterial compliance (AC). The stage of development of impaired arterial function in CKD in relation to loss of glomerular filtration rate (GFR) is not known. This study's aim was to evaluate the relationship between GFR and AC in patients with CKD. METHODS: We recruited 91 men aged > or =60 years with GFR 15-89 ml/min (mean 47 +/- 21) to evaluate the relationship between GFR and AC in a cross-sectional study. We measured AC at the brachial artery with an oscillometric device (brachial artery distensibility; BAD). RESULTS: There was no correlation between GFR and BAD (r = 0.08, p = 0.44). When stratified according to CKD stages, all groups showed decreased BAD compared with reference values, and there were no differences among them (one-way ANOVA). Bivariate analyses showed statistically significant correlations between BAD and age (r = -0.23, p = 0.03), antihypertensive drug number (r = 0.27, p = 0.009) and serum hemoglobin (r = 0.24, p = 0.02), but only age and antihypertensive drug number remained significant markers of BAD in a multiple regression model. CONCLUSION: Older men with CKD have impaired arterial function, but GFR and CKD stage have no relationship to the degree of decrease in brachial artery distensibility.

Aging↗

PubMed2005

Warfarin therapy and systolic hypertension in men with atrial fibrillation.

BACKGROUND: Warfarin decreases the activity of matrix Gla-protein and causes extensive arterial calcification leading to increased systolic blood pressure (SBP) and pulse pressure (PP) in rats. We performed post hoc analyses of the Stroke Prevention in Non-Rheumatic Atrial Fibrillation (SPINAF) trial, aiming to analyze the effects of warfarin on SBP and PP. METHODS: The SPINAF trial was a randomized, double-blind, placebo-controlled trial comparing warfarin and placebo in 525 subjects with nonrheumatic atrial fibrillation. After exclusions for inadequate follow-up, 284 subjects with average treatment lasting 23.7 months were available for analysis (144 given placebo and 140 warfarin). RESULTS: Baseline SBP, diastolic blood pressure (DBP), mean arterial pressure (MAP), and PP were 132 +/- 18, 81 +/- 9, 98 +/- 11, and 50 +/- 16 mm Hg in the warfarin group, and 133 +/- 21, 80 +/- 13, 97 +/- 14, and 54 +/- 15 mm Hg in the placebo groups (all P values, NS). There was no statistically significant difference between the placebo and warfarin groups in any of the BP parameters at any time point. However, stratified analyses showed a significant increase in PP in warfarin-treated subjects with a history of hypertension (4.9 +/- 13.1 mm Hg v 0.2 +/- 11.9 mm Hg in the placebo group, P = 0.022), and those with baseline SBP > or =140 mm Hg (4.8 +/- 18.9 mm Hg v -3.4 +/- 11.2 mm Hg in the placebo group, P = .038). A similar trend was noted in diabetic subjects but it was not statistically significant. CONCLUSIONS: Based on the study results, treatment with warfarin does not result in increased BP in men with atrial fibrillation. However, it is possible that subjects at higher baseline cardiovascular risk may be more susceptible to the chronic effects of warfarin on arterial hemodynamics.

Aged↗

PubMed2005

Hypertension in dialysis.

PURPOSE OF REVIEW: Hypertension is highly prevalent in dialysis patients and may be important to the high cardiovascular mortality of this population. This review shows the current direction in dialysis-associated hypertension management. RECENT FINDINGS: Decreasing dialysate sodium concentration based on pre-hemodialysis plasma sodium concentration may have an additive effect in controlling hypertension. Sympathetic nervous system overactivity is an important feature of end-stage renal disease; a new amine oxidase, renalase, may be relevant to the pathogenesis of hypertension in this population. Similarly, drugs that block the sympathetic nervous system are uniformly protective in dialysis patients. Daily dialysis (short or long) results in better blood pressure control, and the mechanisms resulting in this effect are increasingly better understood. SUMMARY: Long-term control of hypertension is necessary in dialysis patients. The better understanding of the dialysis-associated hypertension pathogenesis has impact on the dialysis prescription and antihypertensive drug choices.

Hemodialysis Solutions↗

PubMed2004

Blood pressure measurement in dialysis patients.

The best method and timing of blood pressure (BP) measurement in end-stage renal disease are subject to controversy. This issue is especially relevant in hemodialysis patients, where unique causes of inaccuracy may exist. The lack of standardization of BP measurement in the dialysis unit may lead to misdiagnosis, so close attention must be paid to technical methods to obtain BP. A composite of BP measurements over a period of 1 to 2 weeks rather than isolated readings should be used for guidance. Interdialytic BP monitoring with an ambulatory BP monitor is the most reproducible method and is thought to best represent BP in dialysis patients. If available, ambulatory BP is a useful tool to evaluate the quality of BP control in the interdialytic period. Alternative forms of BP measurement, such as home BP, 20-minute postdialysis BP, and short (3-hour to 4-hour) ambulatory blood pressure monitoring (ABPM), could prove useful when feasible or available. In this paper, we discuss the evidence regarding BP measurement in dialysis patients, new techniques under development, and recommendations for clinical practice.

Blood Pressure Determination↗

PubMed2004

Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients.

BACKGROUND: Predialysis plasma sodium (Na(+)) concentration is relatively constant in hemodialysis (HD) patients, and a higher dialysate Na(+) concentration can promote an increase in the interdialytic fluid ingestion to achieve an individual's osmolar set point, and individualization of dialysate Na(+) concentration may improve interdialytic weight gain (IDWG), blood pressure (BP), and HD-related symptoms. METHODS: Twenty-seven nondiabetic, non-hypotension prone HD patients were enrolled in a single-blind crossover study. Subjects underwent nine consecutive HD sessions with the dialysate Na(+) concentration set to 138 mEq/L (standard Na(+) HD), followed by nine sessions wherein the dialysate Na(+) was set to match the patients average pre-HD plasma Na(+) measured three times during the standard Na(+) phase multiplied by 0.95 (individualized dialysate Na(+) HD). Dry weight, dialysis prescription, and medications were not modified during the six weeks of the study. RESULTS: Pre-HD Na(+) was similar in both periods of the study (standard Na(+) HD, 134.0 +/- 1.4 mEq/L; individualized Na(+) HD, 134.0 +/- 1.5 mEq/L; P= 0.735). There was a significant decrease in interdialytic weight gain (2.91 +/- 0.87 kg vs. 2.29 +/- 0.65 kg; P< 0.001), interdialytic thirst scores, and episodes of intradialytic hypotension in the individualized Na(+) period compared with the standard phase. Pre-HD BP was lower in individualized Na(+) HD in patients with uncontrolled BP at baseline (N= 15), but not in those with controlled BP at baseline (N= 12) (DeltaBP -15.6/-6.5 mm Hg in uncontrolled vs. DeltaBP +6.4/+4.5 mm Hg in controlled, P= <0.001 for systolic BP and P= <0.001 for diastolic BP). CONCLUSION: An individualized Na(+) dialysate based on predialysis plasma Na(+) levels decreases thirst, IDWG, HD-related symptoms, and pre-HD BP (in patients with uncontrolled BP at baseline).

Adult↗

PubMed2003

Critical issues in nephrology.

Renal and electrolyte problems are common in patients in the ICU. Several advances that occurred in the recent past have been incorporated in the diagnosis and management of these disorders and were reviewed in this article. Unfortunately, many important questions remain unanswered, especially in the area of ARF, where new therapies are anxiously awaited to make the transition from bench to bedside. Better studies are sorely needed to define the best approach to dialysis in patients who have ARF.

Acid-Base Imbalance↗

PubMed2003

The use of peridialysis blood pressure and intradialytic blood pressure changes in the prediction of interdialytic blood pressure in haemodialysis patients.

OBJECTIVE: It is uncertain which blood pressure values (pre- or post-haemodialysis) best represent the average daily blood pressure in haemodialysis patients. The purpose of this study was to verify the power of peridialysis blood pressure to predict interdialytic blood pressure, and to ascertain the influence of blood pressure fluctuations during dialysis on this predictive ability. METHODS AND RESULTS: We performed ambulatory blood pressure monitoring during the interdialytic period on 60 stable haemodialysis patients (mean age 53 +/- 16 years, 33 male) between two mid-week haemodialysis sessions. Pre- and post-haemodialysis blood pressures were 154/82 and 142/77 mmHg, respectively, and 44-h interdialytic blood pressure was 136/77 mmHg. Overall, post-haemodialysis blood pressure values correlated with interdialytic ambulatory blood pressure marginally better than did pre-haemodialysis values (r = 0.52 versus 0.61 for pre- and post-dialysis systolic pressure, respectively; r = 0.67 versus 0.72 for pre- and post-dialysis diastolic pressure, respectively). The average of the pre- and post-haemodialysis values showed a slightly better correlation with interdialytic blood pressure (r = 0.65 and 0.75 for systolic and diastolic pressure, respectively). When we stratified patients according to systolic blood pressure behaviour during dialysis, pre-dialysis blood pressure was the stronger predictor of interdialytic blood pressure in the quartile with greatest intradialytic blood pressure fall (r = 0.67 versus 0.44 for pre- and post-dialysis systolic blood pressure, respectively), whereas post-dialysis values were substantially better in the group with a rise in systolic pressure during dialysis (r = 0.26 versus 0.59 for pre- and post-dialysis systolic blood pressure, respectively). CONCLUSIONS: These data demonstrate that peridialysis blood pressure values are of limited accuracy in predicting interdialytic blood pressure, post-dialysis values are minimally better predictors than pre-dialysis blood pressures, and the average of pre- and post-haemodialysis values is marginally better than both. In addition, blood pressure fluctuations during dialysis have a sizable impact on this predictive ability. Clinical decisions related to blood pressure management and research design in haemodialysis hypertension should take these factors into account.

Blood Pressure↗

PubMed2002

Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance.

PURPOSE OF REVIEW: To evaluate the current value of ambulatory blood pressure monitoring in patients with chronic renal disease and end-stage renal disease. RECENT FINDINGS: Ambulatory blood pressure monitoring has become an important tool in hypertension research and clinical practice. Its use in essential hypertension shows a strong predictive ability in the assessment of cardiovascular outcomes. In chronic renal failure and end-stage renal disease, the role of ambulatory blood pressure monitoring is still being actively evaluated, and available evidence shows that it is better than office blood pressure in predicting left ventricular hypertrophy and progression of renal dysfunction in patients with chronic renal failure. In end-stage renal disease, preliminary data suggest better prediction of mortality in hemodialysis patients in comparison with clinic blood pressures. The most conspicuous problems with the literature on this subject are small sample sizes and the paucity of longitudinal observational studies and intervention trials. SUMMARY: Preliminary data and extrapolations from essential hypertension have justified a growing excitement about the use of ambulatory blood pressure monitoring in renal disease. However, further research will have to address the limitations of the available literature before generalization of its use is implemented.

Blood Pressure Monitoring, Ambulatory↗

PubMedDate not supplied

Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice.

Determining dry weight and assessing extracellular fluid volume in hemodialysis (HD) patients is one of the greatest challenges to practicing nephrologists. The clinical examination has limited accuracy, so different strategies have been investigated to aid in this evaluation. Biochemical markers of volume overload (ANP, BNP, cGMP) are fraught with excessive variability and poor correlation with volume status. Inferior vena cava ultrasound is effective, but cumbersome and costly. Bioimpedance measurements of intra- and extracellular water have significant shortcomings when used as isolated measurements, but can be useful in following trends over time and have been shown to improve intradialytic symptoms and blood pressure control. Continuous blood volume monitoring is helpful in preventing intradialytic hypotension and may help identify patients who are volume overloaded and need increased ultrafiltration. In this review we discuss these different techniques and other developments in the evaluation of dry weight and volume status, which may enhance our ability to improve patient stability and well-being during HD sessions.

Biomarkers↗

PubMedDate not supplied

Profile of interdialytic blood pressure in hemodialysis patients.

BACKGROUND AND METHODS: Hypertension is a common problem in hemodialysis (HD). However, its behavior during the interdialytic period is not completely known and is infrequently monitored in clinical practice. Thus, for better understanding of interdialytic blood pressure (BP), we analyzed the interdialytic blood pressure profile using 44-hour ambulatory blood pressure monitoring (ABPM) data in 71 unselected, stable HD patients. RESULTS: There was an increase in BP during the interdialytic period (awake day 1: 135/84 +/- 23/14 mm Hg; awake day 2: 140/86 +/- 22/15 mm Hg, p < 0.05; sleep day 1: 130/77 +/- 24/15 mm Hg; sleep day 2: 136/80 +/- 24/15 mm Hg, p < 0.05). The correlation between the average 44-hour BP and interdialytic weight gain (IDWG) was not significant (r = -0.07 for systolic BP and r = -0.09 for diastolic BP). The number of non-dipper patients was high, 77% on interdialytic day 1 and 83% on interdialytic day 2 for systolic BP. Uncontrolled hypertension (average 44 h BP > or =135/85 mm Hg) was diagnosed in 58 (55%) patients. Patients with uncontrolled hypertension had higher pre- and posthemodialysis BP, higher BP on each interdialytic day and night, and higher night/day diastolic BP ratio on the second interdialytic day. These patients were also taking a greater number of vasoactive medications (1.5 vs. 0.6 in those with controlled BP, p = 0.001). There were no significant differences related to kt/V, hematocrit, or weekly erythropoietin dose between patients with controlled or uncontrolled BP. Hemodialysis shift assignment (morning or afternoon) did not impact on BP levels or diurnal profile. CONCLUSION: In HD patients, interdialytic BP is often poorly controlled, there is a progressive rise in BP, and a trend toward loss of nocturnal decline in BP as the interdialytic period progresses. Further research is needed to determine whether treatment directed to interdialytic BP changes can alter outcomes in HD patients.

Antihypertensive Agents↗